Report Of MDA Muscle Disease Symposium On Newborn Screening For Duchenne Muscular Dystrophy

Muscle and Nerve

Volumn 48, Issue 1, 2013, Pages 21-26

  Mendell, Jerry R ^a   Lloyd Puryear, Michele ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Committee on Heritable Disorders for Newborns and Children; Department of Health and Human Services; Duchenne muscular dystrophy; Newborn Screening; Recommended Uniform Screening Panel; Secretary's Advisory

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CREATINE KINASE; DYSTROPHIN; GLUCOCORTICOID;

5' UNTRANSLATED REGION; ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; DNA DETERMINATION; DNA SCREENING; DNA SEQUENCE; DRIED BLOOD SPOT TESTING; DUCHENNE MUSCULAR DYSTROPHY; EARLY INTERVENTION; EXON; EXON SKIPPING; FOLLOW UP; GENETIC ANALYSIS; HUMAN; MOTOR PERFORMANCE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NEWBORN SCREENING; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION;

GENETIC TESTING; HUMANS; INFANT, NEWBORN; MARYLAND; MUSCULAR DYSTROPHY, DUCHENNE; NEONATAL SCREENING; RESEARCH REPORT;

EID: 84879555922     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23810     Document Type: Article

References (19)

1. Roberto R, Fritz A, Hagar Y, Boice B, Skalsky A, Hwang H, et al. The natural history of cardiac and pulmonary function decline in patients with Duchenne muscular dystrophy. Spine 2011;36:E1009-E1017.
2. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley RT III, Miller JP, et al. Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve 1983;6:91-103.
3. Mendell JR, Mosley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989;320:1592-1597.
4. King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007;68:1607-1613.
5. Merlini L, Gennari M, Malaspina E, Cecconi I, Armaroli A, Gnudi S, et al. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve 2012;45:796-802.
6. Connolly AM, Florence, JM, Cradock MM, Malkus E, Schierbecker J, Siener C, et al. Motor and cognitive assessment of infants and young boys with Duchenne muscular dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. P04.084 American Academy of Neurology Meeting Abstracts April 25, 2012.
7. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 2012;71:304-313.
8. Flanigan KM, von Niederhausern A, Dunn DM, Alder J, Mendell JR, Weiss RB. Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet 2003;7:931-939.
9. Zeng F, Ren ZR, Huang SZ, Kalf M, Mommersteeg M, Smit M, et al. Array-MLPA: comprehensive detection of deletions and duplications and its application to DMD patients. Hum Mutat 2008;29:190-197.
10. Hedge MR, Chin EL, Mulie JG, Odou DT, Warren ST, Zwick ME. Microarray-based mutation detectin in the dystrophin gene. Hum Mutat 2008;29:1091-1099.
11. Tanner AK, Chin EL, Duffner PK, Hegde M. Array CGH improves detection of mutations in the GALC gene associated with Krabbe disease. Orphanet J Rare Dis 2012;7:38.
12. Valencia CA, Rhodenizer D, Bhide S, Chin E, Littlejohn MR, Keong LM, et al. Assessment of target enrichment platforms using massively parallel sequencing for the mutation detection for congenital muscular dystrophy. J Mol Diagn 2012;14:233-246.
13. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007;357:2677-2686.
14. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009;8:918-928.
15. Goemans NM, Tulinius M, Van Den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011;1513-1522.
16. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose- escalation study. Lancet 2011;378:595-605.
17. Griggs RC, Moxley RT III, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Arch Neurol 1991;48:383-388.
18. Arnold CL, Davis TC, Frempong JO, Humiston SG, Bocchini A, Kennen EM, et al. Assessment of newborn screening parent education materials. Pediatrics 2006;117(Pt 2):S320-S325.
19. Hinton CF, Neuspiel DR, Gubernick RS, Geleske T, Healy J, Kemper AR, et al. Improving newborn screening follow-up in pediatric practices: quality improvement innovation network. Pediatrics 2012;130:e669-e675.